To appraise the clinical and cost effectiveness of dapagliflozin and empagliflozin within their marketing authorisation for treating type 1 diabetes.
Following comments received in the draft scope consultation NICE decided to split this Multiple Technology Appraisal (MTA) of three drugs into three separate Single Technology Appraisals (STAs). The STAs are: [ID1478] – dapagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10374) [ID1376] – sotagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10376) [ID1275] – empagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10375). This MTA is therefore suspended.
 
Status Discontinued
Process MTA
ID number 1217

Project Team

Project lead Jeremy Powell

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
12 June 2018 Discontinued, Following comments received in the draft scope consultation NICE decided to split this Multiple Technology Appraisal (MTA) of three drugs into three separate Single Technology Appraisals (STAs). The STAs are: [ID1478] – dapagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10374) [ID1376] – sotagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10376) [ID1275] – empagliflozin (https://www.nice.org.uk/guidance/indevelopment/gid-ta10375). This MTA is therefore suspended.
15 March 2018 In progress, Topic referred 13 February 2018
07 November 2017 (00:00) Scoping workshop
19 September 2017 - 17 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance